The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse < 6 months from end of therapy (early relapse; ER). Median age was 58 years and response to salvage was 41.7%. Two-year OS was 18.5% in PP, 30.6% in RD and 45.5% in ER. The presence of PP, intermediate-high/high NCCN-IPI at time of PTF or MYC translocation predicted 2-year OS of 13.6% constituting ultra-high risk (UHR) features. Among the 132 patients who underwent autologous hematopoietic cell transplantation, 2-year OS was 74.3%, 59.6% and 10.7% for patients with 0,1 and 2-3 UHR features respectively. Patients with PTF and UHR features should be prioritized for clinical trials with newer agents and innovative cellular therapy.
| I N T R O D U C T I O N
The majority of patients with diffuse large B-cell lymphoma (DLBCL) will be cured with chemotherapy in combination with rituximab. [1] [2] [3] [4] Complete remission (CR) is a requirement for cure and is achieved after initial therapy in approximately 70%-95% of patients, depending on disease and patient features. [1] [2] [3] [4] Patients who obtain a CR and later experience disease recurrence can often be treated with salvage chemotherapy regimens, and subsequently autologous hematopoietic cell transplantation (auto-HCT). 5, 6 Patients who fail to obtain a CR or progress during initial chemoimmunotherapy are expected to have a worse prognosis than relapsed patients. 7, 8 Similarly, patients who obtain a brief CR and quickly evolve with progressive disease have a very poor prognosis. 5 Collectively, these patients can be grouped as having primary treatment failure (PTF). Most of the recent literature or clinical trials have analyzed PTF and patients with later relapse together and physicians treating PTF patients tend to use the same treatment paradigms applicable for patients with late relapses. 5, 9 Some data from the pre-rituximab era indicate very dismal prognosis for PTF patients, [10] [11] [12] but little is known about this group of patients in the setting of more modern upfront and salvage therapies.
Therefore contemporary information on the outcome of PTF patients is needed.
Prognostic scores have been generated, validated, and are widely used in newly diagnosed DLBCL 4,13 including the recently described
National Comprehensive Cancer Network International Prognostic
Index (NCCN-IPI). 13 Some factors are also well known to affect the survival of DLBCL patients who relapse after initial chemoimmunotherapy, including international prognostic index (IPI) and time to relapse. 5, 14, 15 However, there has not been any prognostic system dedicated to predicting outcomes of PTF patients. It is crucial to identify factors linked to poor outcomes with current therapeutic approaches so that these patients can be routed to experimental approaches early in the course of their diseases. In addition, the knowledge of outcomes in different subsets of PTF patients will provide benchmarking for future experimental approaches for this population. sen using a stepwise backward process with a probability of entry of .05 and a probability of removal of .10. Formal testing revealed that predictors included in Cox proportional hazards models satisfied the assumption of proportionality. A two-sided P-value .05 was considered statistically significant. All analyses were conducted using IBM SPSS (v22.0).
| M E T H O D S

| R E S U LTS
A total of 389 cases were submitted for analysis. After quality check and queries of reporting institutions, 331 cases were considered valid and maintained in the final analysis. Overall 7 cases were excluded for being primary CNS lymphoma, 8 cases for being trans- 
| Salvage therapy and outcomes
At the time of PTF, the vast majority of patients (94.6%) received therapy (Table 1) . In most cases, an aggressive, multi-agent chemotherapy regimen often combined with rituximab as the first salvage therapy, was used, likely reflecting intent to proceed with transplant consolidation. Enrollment on a clinical trial for salvage therapy was 15.1%.
Overall response rate to first regimen of salvage therapy was 41.7%. A higher proportion of patients in PP (52.1%) than in ER (31.6%) or RD (32.6%) had disease progression while on first salvage regimen. Overall, less than a third of patients obtained CR to the first or any subsequent regimen utilized in the salvage setting and prior to transplantation. CRs were however more common in ER (54.7%) than in RD (19.6%) or in PP patients (18.1%). Auto-HCT was performed as consolidation for 132 patients and allogeneic HCT (allo-HCT) for 33 patients, including 8 who received allo-HCT following progression after auto-HCT.
| Survival
Survival was influenced by the pattern of PTF. Two-year OS was 18.5% (95% C.I. 11.4%-25.6%) in PP cases, 30.6% (95% C.I. 20.0%-41.2%) in RD, and 45.5% (95% C.I. 34.5%-56.5%) in ER (P < .001, Figure 1A ). Survival was worse in MYC(1) than in MYC(2) cases ( Figure 1B ), but no difference was detected between single-hit and double-hit cases (P 5 .7, Figure 1B ). There was also no significant survival difference between GCB and NGC cases (2-year survival 24.7% vs. 40.4%, P 5 .14, Figure 1C ). As expected, the vast majority of MYC(1) patients, 48/56 (86%), were GCB, while only 3/56 (5%)
were NGC and 5/56 (9%) could not be classified. We subsequently explored the combined effect of MYC and COO on survival.
Patients with MYC(1) lymphoma had worse survival than MYC (2)/GCB (2-year OS 9.3% vs. 34.9%, P < .001) and MYC(2)/NGC (9.3% vs. 38.6%, P 5 .006). There was no significant OS difference between MYC(2)/GCB and MYC(2)/NGC (P 5 .9, Figure 1D ). Figure 1E ).
| Identification of ultra-high risk features
We subsequently performed multivariate analysis to identify variables known at the time of PTF and that independently affect outcome. As the intent was to identify patients who were predicted to do poorly We subsequently analyzed the impact of the presence of UHR features on OS in a subset of 144 patients with complete information on the pattern of PTF, MYC status and NCCN-IPI at time of PTF. The presence of any of these factors predicted 2-year OS of only 13.6% (95% C.I. 5.8%-21.4%) versus 57.6% (95% C.I 40.6%-74.7%) for patients with PTF and no UHR features (P < .001, Figure 1F ).
| Transplant outcomes
One hundred and thirty-two patients underwent auto-HCT and 33 allo-HCT, including 8 patients who underwent allo-HCT after prior failed auto-HCT. Transplantation (autologous or allogeneic) was achieved in 67/108 (62%) patients with 0 versus 62/132 (47%) patients with 1 versus 28/91 (31%) patients with 2 or 3 UHR features (P < .001). Patient and transplant characteristics are displayed in Table 2 .
The majority of patients who underwent auto-HCT did so after have chemosensitive disease and proceed with auto-HCT. MYC (1) tumors constitute only 5%-10% of newly diagnosed cases of DLBCL and are a strong prognostic factor either alone or associated with additional translocations involving BCL2 and/or BCL6. 18, 19, 21 As expected, there is enrichment for MYC(1) cases among patients with relapsed disease and PTF. In fact, a subsequent analysis of the population enrolled in the CORAL study found that 17% of cases (N 5 28) were MYC(1) and those patients had worse PFS and OS than remaining patients, even when they responded to salvage therapy and underwent auto-HCT. 20 Our analysis, by focusing on a subset of patients with more aggressive disease than the CORAL study, found an even higher proportion of MYC (1) Putative cell or origin is associated with prognosis in patients with newly diagnosed DLCBL, 17 but its prognostic implication in patients with relapsed or refractory disease is less clear. For instance, in the Bio-CORAL study, 23 COO was prognostic among patients treated with R-DHAP regimen, but not among patients treated with R-ICE. We did not find a significant survival difference between GCB and NGC-type cases in our series. As GCB with PTF are enriched for MYC(1) cases the analysis of the simultaneous effect of MYC status and COO on survival further emphasizes the lack of independent impact of COO on survival of patients with PTF. In fact, in multivariate analysis that included MYC status, COO had no significant impact on OS. Similar observation was also made in the University of Iowa/Mayo Clinic study. 7 As patients with NGC have lower chance of CR and shorter survival than their GCB counterparts, a cohort of patients with PTF would be expected to be enriched for NGC cases. However, only about a third of cases where COO could be determined were of NGC type.
We believe such discrepancy mostly reflect cases with incomplete immunohistochemistry panels preventing identificaton of NGC origin.
For example, while CD10(1) suffices for identificatin of GCB origin, CD10(2) with no information on BCL6 or MUM1 precludes identification of COO. The retrospective nature of the present study imposes some caveats, such as the lack of central pathology review, missing data and the heterogeneity of population and treatments. Conversely, our analysis offers a "real world" insight into treatment choices and results for this challenging population. Yet, as the study resulted from a collaboration of academic centers, it is very likely that the population represented is biased toward younger and fit patients. In fact, the median age of patients included in the analysis (58 years) was much lower than the median age of individuals diagnosed with DLBCL in the US (67 years).
Despite this possible bias and the expected poor outcomes with existing treatments, only 1 in 6 patients participated in a therapeutic clinical trial during salvage therapy.
The outcomes of patients who underwent auto-HCT in this series are in line with a recent CIBMTR report on 300 patients with early rituximab failure (defined as not achieving CR or having relapse <12 months from diagnosis). 6 In that study, 3-year PFS and OS for these patients was 44% and 50%, respectively, outcomes that are somewhat comparable to 2-year PFS and OS of 38.4% and 54.9% respectively in REFINE, although we included a higher risk population by limiting relapse to 6 months from completion of therapy and including patients with primary progressive disease. The outcomes of REFINE are also comparable with the subset of patients in CORAL 5 who had received prior rituximab and developed ER (<12 months from diagnosis). For those patients, 3-year PFS was 23%, while patients who responded to salvage therapy and underwent auto-HCT had 3-year PFS of 39% (vs.
2-year PFS of 38.4% in REFINE).
Allogeneic transplant can be an effective therapy for DLBCL, particularly for patients who relapse after auto-HCT. 24 Its efficacy resides on graft versus lymphoma (GVL) effect in addition to the cytotoxic effect of the conditioning regimen. Outcomes of allo-HCT in REFINE were disappointingly poor with failures occurring predominantly because of fast disease progression. This suggests that since GVL requires a significant time to establish, it is unable to overcome rapidly growing disease.
Our findings confirm those of the CORAL and CIBMTR study that a subset of patients with early treatment failure after rituximabcontaining chemoimmunotherapy and chemo sensitive disease can be cured with auto-HCT. These studies analyzed a subset of patients with progression or recurrence less than 12 months from diagnosis, therefore approximately 6 months from the end of therapy as in REFINE. Additionally, it indicates that the assessment of three simple parameters:
pattern of failure, MYC status, and NCCN-IPI at time of PTF can identify patients with dramatically distinct prognosis. While for patients with no more than 1 UHR feature intensive salvage therapy followed by auto-HCT for chemosensitive disease should remain the standard of care, patients with 2 or 3 UHR feature should be prioritized for experimental approaches, as those patients have low likelihood of achieving transplantation and, if they do, have very poor outcomes. Such experimental therapies include new biological agents and particularly the use of Tcells expressing antigen-specific chimeric antigen receptors as standalone therapy 25 or in the setting of auto-HCT 26, 27 or allo-HCT. 28, 29 In summary, REFINE provides information on treatment patters and outcomes of DLBCL with PTF, identifies UHR features that predict poor outcomes and provides benchmarking for innovative therapies focused on this special patient population. 
